Postmortem Cannabis Testing: A Validated Extraction Does Not Reconstruct Life Before Death

A method that successfully extracts THC from postmortem specimens establishes analytical capability. It does not independently establish how the deceased behaved before death or whether cannabis caused an accident.

What the laboratory developed

Researchers developed a liquid–liquid extraction and gas chromatography–mass spectrometry method for THC and THC-COOH, applying it to 41 postmortem samples. The workflow used separate extraction conditions for parent THC and its carboxy metabolite, with derivatization for the latter.

This was human-specimen analytical research, not controlled dosing of living participants. The study assessed detection, calibration, precision, accuracy and recovery. Those endpoints address measurement performance rather than functional impairment.

The exact matrix still matters

Although the paper describes postmortem blood, its preparation section states that plasma was separated by centrifugation when possible. That qualification matters when evaluating a result attributed simply to “blood.” Whole blood and separated plasma are different preparations and should be identified accurately in a case report.

The authors discuss practical difficulties with degraded postmortem samples, including problems passing material through solid-phase extraction cartridges. A method’s practical usefulness in that setting does not eliminate specimen heterogeneity.

Validation is not a causal experiment

The method showed acceptable analytical precision and accuracy under its validation conditions. The case application demonstrated that the workflow could be used on actual submissions. It did not validate a conversion from a postmortem concentration to a living person’s earlier concentration or performance.

THC and THC-COOH must also remain separate: parent drug and an inactive carboxy metabolite do not answer the same toxicological question. The presence of either requires interpretation with collection site, timing, preparation and other case evidence.

Questions an opinion should answer

Ask which specimen was actually extracted, whether the laboratory’s own validation covers its condition, and which inference the analyst proposes. An accurate concentration can support exposure evidence while leaving impairment, timing and cause of death unresolved. Analytical success should not be used to fill those evidentiary gaps.

For context, see our discussion of THC concentrations and the separate question of impairment.

Primary research

Ivan Álvarez-Freire and colleagues. Simple Method for the Determination of THC and THC-COOH in Human Postmortem Blood Samples by Gas Chromatography—Mass Spectrometry. Molecules (2023). DOI: 10.3390/molecules28083586.

Spread the love


The National Black Lawyers

top 40 lawyers

civil trial law

Lawyers of Distinction

Loading...

Recent Blog Articles

A Higher Edible Dose Did Not Produce a Higher Mean Blood THC Peak in Every Group

A 50 mg edible THC dose did not produce a higher mean whole-blood THC peak than 25 mg in a small between-group study. That observation does not show reversed absorption or make blood concentration a reliable dose calculator. Only six people received each dose Healthy adults without recent cannabis use…

Spread the love

Read Article: A Higher Edible Dose Did Not Produce a Higher Mean Blood THC Peak in Every Group

Oral-Fluid Parent Cannabinoids and Metabolites Followed Different Route Patterns

An oral-fluid THC peak immediately after cannabis use can reflect material deposited in the mouth rather than peak systemic exposure. A controlled comparison of smoked, vaporized and edible cannabis found different route patterns for parent cannabinoids and metabolites. Within-person route comparisons Eleven frequent and nine occasional cannabis smokers completed a…

Spread the love

Read Article: Oral-Fluid Parent Cannabinoids and Metabolites Followed Different Route Patterns

Transdermal CBD’s Open-Label Seizure Improvement Did Not Reverse Its Blinded Null Result

Transdermal CBD did not significantly reduce seizure frequency compared with placebo during a blinded adult focal-epilepsy trial. Improvement during the later open-label extension answered a different question and did not overturn that randomized comparison. A daily-dose distinction clarified by correction The trial randomized 188 adults to transdermal CBD or placebo….

Spread the love

Read Article: Transdermal CBD’s Open-Label Seizure Improvement Did Not Reverse Its Blinded Null Result

Speak with an expert today!

Contact the offices of Okorie Okorocha for professional and reliable advice which you can trust.

Call (424) 363-3347 Contact Us